Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Otsuka Holdings Co ( (JP:4578) ) has shared an update.
Otsuka Holdings Co. announced promising 12-month interim results from its Phase 3 VISIONARY trial for sibeprenlimab, a treatment for immunoglobulin A nephropathy (IgAN). The trial showed a significant reduction in proteinuria, a marker for kidney disease progression, with a favorable safety profile. The company has filed a Biologics License Application with the U.S. FDA, receiving a Priority Review designation, which could enhance its market position in nephrology treatments.
The most recent analyst rating on (JP:4578) stock is a Buy with a Yen9366.00 price target. To see the full list of analyst forecasts on Otsuka Holdings Co stock, see the JP:4578 Stock Forecast page.
More about Otsuka Holdings Co
Otsuka Holdings Co., Ltd. operates in the pharmaceutical industry, focusing on innovative treatments and healthcare solutions. The company is known for developing novel drugs and therapies, with a market focus on addressing unmet medical needs.
YTD Price Performance: -1.84%
Average Trading Volume: 1,116,386
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen4415.6B
Find detailed analytics on 4578 stock on TipRanks’ Stock Analysis page.